<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00871182</url>
  </required_header>
  <id_info>
    <org_study_id>PT0010801</org_study_id>
    <nct_id>NCT00871182</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Safety and Efficacy of Inhaled PT001 in Patients With Chronic Obstructive Pulmonary Disease (COPD)</brief_title>
  <official_title>A Randomized, Double-blind, Single Dose, Four-period, Six-treatment, Placebo-controlled, Balanced, Incomplete Block, Cross-over, Study of Four Doses of Inhaled PT001 in Patients With Mild to Moderate COPD, Compared to Open Label Tiotropium</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pearl Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pearl Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of inhaled PT001 compared to
      placebo and tiotropium in patients with mild to moderate chronic obstructive pulmonary
      disease (COPD).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peak improvement in forced expiratory volume in one second (FEV1)</measure>
    <time_frame>Day 1</time_frame>
    <description>Day 1 serial FEV1 measured over 24 hours</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to onset of action (&gt;10% improvement in FEV1 from baseline)</measure>
    <time_frame>Day 1</time_frame>
    <description>Day 1 serial FEV1 measured over 24 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to peak FEV1</measure>
    <time_frame>Day 1</time_frame>
    <description>Day 1 serial FEV1 measured over 24 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 area under the curve (AUC) from 0 to 24 hours</measure>
    <time_frame>Day 1</time_frame>
    <description>Day 1 serial FEV1 measured over 24 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 AUC from 0 to 12 hours</measure>
    <time_frame>Day 1</time_frame>
    <description>Day 1 serial FEV1 measured over 24 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough FEV1 at 12 and 24 hours</measure>
    <time_frame>Day 1</time_frame>
    <description>Day 1 serial FEV1 measured over 24 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Improvement in inspiratory capacity (IC)</measure>
    <time_frame>Day 1</time_frame>
    <description>Day 1 serial IC measured over 24 hours</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>PT001 18 mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inhaled PT001 18 mcg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PT001 36 mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inhaled PT001 36 mcg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PT001 72 mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inhaled PT001 72 mcg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PT001 144 mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inhaled PT001 144 mcg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Inhaled Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Inhaled Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tiotropium Handihaler</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tiotropium 18 mcg administered via Handihaler</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Inhaled PT001</intervention_name>
    <description>single dose, inhaled</description>
    <arm_group_label>PT001 18 mcg</arm_group_label>
    <arm_group_label>PT001 36 mcg</arm_group_label>
    <arm_group_label>PT001 72 mcg</arm_group_label>
    <arm_group_label>PT001 144 mcg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Inhaled Placebo</intervention_name>
    <description>single dose, inhaled</description>
    <arm_group_label>Inhaled Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tiotropium Handihaler</intervention_name>
    <description>single dose, tiotropium 18 mcg administered via the Handihaler</description>
    <arm_group_label>Tiotropium Handihaler</arm_group_label>
    <other_name>Spiriva</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed written informed consent

          -  40 - 75 years of age

          -  Females of non-child bearing potential or females of child bearing potential with
             negative pregnancy test; and acceptable contraceptive methods

          -  COPD diagnosis

          -  Current/former smokers with at least a 10 pack-year history of cigarette smoking

          -  Patients with established clinical history of COPD and severity defined as a
             post-ipratropium FEV1/FVC ratio of ≤0.70 and FEV1 ≥50 and ≤85% of predicted normal at
             Screening

          -  Must demonstrate reversibility to ipratropium demonstrated by a &gt;200 mL improvement
             over baseline and/or &gt;12% and &gt;150 mL improvement over baseline

          -  Patients willing to stay at study site for at least 24 hours on each test day

        Exclusion Criteria:

          -  Women who are pregnant or lactating

          -  Primary diagnosis of asthma

          -  Alpha-1 antitrypsin deficiency as the cause of COPD

          -  Active pulmonary diseases

          -  Prior lung volume reduction surgery

          -  Abnormal chest X-ray (or CT scan) not due to the presence of COPD

          -  Hospitalized due to poorly controlled COPD within 24 weeks of Screening

          -  Unable to perform acceptable spirometry

          -  Poorly controlled COPD in prior 6-weeks, defined as the occurrence of acute worsening
             of COPD requiring corticosteroids or antibiotics or acute worsening of COPD requiring
             treatment prescribed by a physician

          -  Clinically significant medical conditions

          -  Symptomatic prostatic hypertrophy or bladder neck obstruction

          -  Known narrow-angle glaucoma

          -  Lower respiratory tract infection requiring antibiotics in past 6 weeks

          -  Clinically significant abnormal ECG

          -  Clinically significant uncontrolled hypertension

          -  Positive Hepatitis B surface antigen or Hepatitis C antibody

          -  Cancer that has not been in complete remission for at least 5 years

          -  History of hypersensitivity to any beta2-agonists or anticholinergics

          -  History of severe milk protein allergy

          -  Known or suspected history of alcohol or drug abuse

          -  Medically unable to withhold short acting bronchodilators for 6-hours

          -  Use of the medications below in specified time interval prior to Screening: 3 months:
             depot corticosteroids, intra-articular corticosteroids; 6 weeks: oral corticosteroids,
             antibiotics administered for a COPD exacerbation; and 1 month: P-glycoprotein
             inhibitors, CYP450 3A4 inhibitors, ICS &gt;1000 μg/day of fluticasone propionate or
             equivalent

          -  The following COPD medications need to be stopped and switched to appropriate
             replacement therapies: tiotropium, oral beta2 agonists, LABAs, combination
             corticosteroid/LABAs, theophylline, leukotriene inhibitors,cromoglycate and nedocromil

          -  Use of the following medications is prohibited: tricyclic antidepressants, monoamine
             oxidase (MAO) inhibitors, beta-adrenergic antagonists, anticonvulsants (barbiturates,
             hydantoins, and carbamazepine and phenothiazines

          -  Receiving long-term-oxygen or nocturnal oxygen therapy for &gt;12 hours a day

          -  Diagnosis of sleep apnea that is uncontrolled

          -  Participation in acute phase of pulmonary rehabilitation in prior 4 weeks

          -  Will enter acute phase of pulmonary rehabilitation program during study

          -  Unable to comply with study procedures

          -  Affiliated with Investigator site

          -  Questionable validity of consent

          -  Use of investigational study drug/participation in clinical study in the last 30 days
             or 5 half lives prior to Screening, whichever is longer
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Colin Reisner, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Pearl Therapeutics, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pivotal Research Centers</name>
      <address>
        <city>Peoria</city>
        <state>Arizona</state>
        <zip>85381</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Jewish Health</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Elite Research Institute</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33169</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pulmonary and Critical Care Medicine</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati VAMC</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spartanburg Medical Research</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 26, 2009</study_first_submitted>
  <study_first_submitted_qc>March 27, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 30, 2009</study_first_posted>
  <disposition_first_submitted>August 24, 2010</disposition_first_submitted>
  <disposition_first_submitted_qc>August 24, 2010</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">August 27, 2010</disposition_first_posted>
  <last_update_submitted>June 12, 2013</last_update_submitted>
  <last_update_submitted_qc>June 12, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 21, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COPD</keyword>
  <keyword>obstructive lung diseases</keyword>
  <keyword>Tiotropium</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tiotropium Bromide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

